Joseph Robert Podojil

  • 1500 Citations

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Dr. Podojil’s work has focused on the role of costimulatory molecule expression and function on both CD4+ T cells and APC populations during autoimmune diseases, such as multiple sclerosis, and he has a particular interest in neuroimmunology. His primary research focus is to determine the cellular and molecular mechanisms underlying the differential effect of structurally modified forms of anti-CD80 monoclonal antibody (mAb) in the CD4+ Th1 cell mediated disease model of PLP139-151-induced EAE. His current findings suggest that stimulation of CD80 on a CD4+ T cell activated in Th1-promoting conditions induces an increase in the amount of IFN-¿ produced per cell and increases Th1 cell survival within the CNS. These findings suggesting a mechanism by which anti-CD80 mAb treatment of PLP139-151-primed mice exacerbates disease, while treatment with anti-CD80 Fab fragments decrease disease severity. In line with his research studying the role of CD80 expression and reverse signaling to the cell expressing CD80, he has also been studying the role of B7-H4 in CD4+ T cell function. B7-H4 is a recently discovered B7-family member molecule hypothesized to inhibit effector CD4+ T cell responses. Since current approaches for regulation of human autoimmune diseases are largely broad-based immunosuppressive strategies necessitating the physical deletion/inhibition of entire subsets of T cells or non-specific inhibition of antigen presentation or pro-inflammatory cytokine production which could compromise the host’s ability to combat opportunistic pathogens and/or increase risk of neoplasia, therefore we are currently investing the ability of short-term therapy with B7-H4 Ig may prove to be clinically viable.

Training Experience

2010Postdoctoral Fellowship, Northwestern University Feinberg School of Medicine

Education/Academic qualification

PhD, Loyola University/Stritch School of Medicine

… → 2004

Research interests

  • Autoimmune Diseases
  • Diabetes
  • Endocrinology
  • Immunology
  • Multiple Sclerosis
  • Neuroscience

Fingerprint Dive into the research topics where Joseph Robert Podojil is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


  • Research Output

    • 1500 Citations
    • 29 Article
    • 5 Review article
    • 1 Chapter

    Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma

    Podojil, J. R., Glaser, A. P., Baker, D., Courtois, E. T., Fantini, D., Yu, Y., Eaton, V., Sivajothi, S., Chiang, M., Das, A., McLaughlin, K. A., Robson, P., Miller, S. D. & Meeks, J. J., Jan 1 2020, In : OncoImmunology. 9, 1, 1744897.

    Research output: Contribution to journalArticle

    Open Access
  • Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease

    Freitag, T. L., Podojil, J. R., Pearson, R. M., Fokta, F. J., Sahl, C., Messing, M., Andersson, L. C., Leskinen, K., Saavalainen, P., Hoover, L. I., Huang, K., Phippard, D., Maleki, S., King, N. J. C., Shea, L. D., Miller, S. D., Meri, S. K. & Getts, D. R., May 2020, In : Gastroenterology. 158, 6, p. 1667-1681.e12

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles

    Pearson, R. M., Podojil, J. R., Shea, L. D., King, N. J. C., Miller, S. D. & Getts, D. R., Jun 2019, In : Nanomedicine: Nanotechnology, Biology, and Medicine. 18, p. 282-291 10 p.

    Research output: Contribution to journalReview article

  • 11 Scopus citations

    Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis

    Chen, Y., Podojil, J. R., Kunjamma, R. B., Jones, J., Weiner, M., Lin, W., Miller, S. D. & Popko, B., Feb 1 2019, In : Brain. 142, 2, p. 344-361 18 p.

    Research output: Contribution to journalArticle

  • 11 Scopus citations

    APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response

    Glaser, A. P., Fantini, D., Wang, Y., Yu, Y., Rimar, K. J., Podojil, J. R., Miller, S. D. & Meeks, J. J., 2018, In : Oncotarget. 9, 4, p. 4537-4548 12 p.

    Research output: Contribution to journalArticle

  • 24 Scopus citations